VRSN insider filing: 501 shares to be sold via Morgan Stanley
Rhea-AI Filing Summary
VeriSign Inc. Form 144 notifies a proposed sale of 501 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $132,514.50, an approximate sale date of 08/12/2025 and listing on NASDAQ. The filing reports total shares outstanding of 93,400,000.
The 501 shares to be sold were acquired as 134 performance shares on 02/13/2025 and 367 restricted stock on 02/15/2025. The filing also lists multiple sales by Thomas C. Indelicarto in the past three months, including sales of 501 shares on 08/05/2025, 07/08/2025, 07/01/2025, 06/10/2025, 06/03/2025 and 05/20/2025, and two partial sales on 05/27/2025 (258 and 243 shares), with gross proceeds reported for each sale in the filing.
Positive
- None.
Negative
- None.
Insights
TL;DR: Proposed sale is immaterial relative to outstanding shares; repeated small filings indicate routine sales, limited near-term market impact.
The filing shows a proposed disposition of 501 shares against 93,400,000 shares outstanding, representing roughly 0.0005% of the float, which is immaterial from a market-cap perspective. The shares were recently acquired via compensation (performance shares and restricted stock) in February 2025. Multiple sales by the named seller are disclosed in the past three months, but sizes and frequency are small relative to total outstanding shares, suggesting low likelihood of material investor impact based on the notice alone.
TL;DR: Repeated Form 144 disclosures document ongoing sales by the named individual; documentation is standard and does not itself imply undisclosed company information.
The filing identifies the broker as Morgan Stanley Smith Barney LLC and documents that the 501 shares offered were acquired as performance awards (02/13/2025) and restricted stock (02/15/2025). The record of several transactions by Thomas C. Indelicarto in recent months is clearly disclosed. From a governance and disclosure standpoint, the form provides required transparency but contains no statements of material adverse information or indications of policy breaches.